Strategic report Governance & remuneration Financial statements Investor information Financial statements of GlaxoSmithKline plc prepared under UK GAAP Disclosure of information to auditors Directors statement of responsibilities The Directors in ofce at the date of this Annual Report have each in relation to the companys financial confirmed that: statements so far as he or she is aware, there is no relevant audit information The Directors are responsible for preparing the parent company, of which the companys auditors are unaware: and GlaxoSmithKline plc, financial statements and the Remuneration he or she has taken all the steps that he or she ought to have report in accordance with applicable law and regulations.
taken as a Director to make himself or herself aware of any UK company law requires the Directors to prepare financial relevant audit information and to establish that the companys statements for each financial year.
Under that law the Directors auditors are aware of that information.
have elected to prepare the parent company financial statements This conrmation is given and should be interpreted in accordance in accordance with United Kingdom Accounting Standards and with the provisions of section 418 of the Companies Act 2006. applicable law United Kingdom Generally Accepted Accounting Practice.
Under company law the Directors must not approve the Going concern basis parent company financial statements unless they are satisfied that After making enquiries, the Directors have a reasonable they give a true and fair view of the state of affairs of the company expectation that the company has adequate resources to continue for that period.
in operational existence for the foreseeable future.
For this reason, they continue to adopt the going concern basis in preparing the In preparing those financial statements, the Directors are required financial statements.
to: The UK Corporate Governance Code select suitable accounting policies and then apply them The Board considers that GlaxoSmithKline plc applies the consistently: principles and provisions of the UK Corporate Governance make judgements and accounting estimates that are reasonable Code maintained by the Financial Reporting Council, as described and prudent: in the Corporate Governance section on pages 78 to 95, and has complied with its provisions.
The Board further considers state with regard to the parent company financial statements that the Annual Report, taken as a whole, is fair, balanced and that applicable UK Accounting Standards have been followed, understandable, and provides the information necessary for subject to any material departures disclosed and explained in shareholders to assess the Groups performance, business the parent company financial statements: model and strategy.
prepare the financial statements on a going concern basis As required by the Financial Conduct Authoritys Listing Rules, unless it is inappropriate to presume that the Group will continue the auditors have considered the Directors statement of in business.
compliance in relation to those points of the UK Corporate The Directors are responsible for keeping adequate accounting Governance Code which are specified for their review.
records that are sufficient to show and explain the companys transactions and disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the parent company financial statements and Remuneration report comply with the Companies Act 2006.
They are also responsible Sir Christopher Gent for safeguarding the assets of the company and hence for taking Chairman reasonable steps for the prevention and detection of fraud and 26 February 2015 other irregularities.
The parent company financial statements for the year ended 31 December 2014, comprising the balance sheet for the year ended 31 December 2014 and supporting notes, are set out on pages 213 to 216 of this report.
The responsibilities of the auditors in relation to the parent company financial statements are set out in the Independent Auditors report on page 212.
The financial statements for the year ended 31 December 2014 are included in the Annual Report, which is published in printed form and made available on our website.
The Directors are responsible for the maintenance and integrity of the Annual Report on our website in accordance with UK legislation governing the preparation and dissemination of financial statements.
Access to the website is available from outside the UK, where comparable legislation may be different.
The Strategic Report and risk sections of the Annual Report include a fair review of the development and performance of the business and the position of the company and the Group taken as a whole, together with a description of the principal risks and uncertainties that it faces.
GSK Annual Report 2014 211 Strategic report Governance & remuneration Financial statements Investor information Independent Auditors report to the members of GlaxoSmithKline plc Report on the parent company financial Responsibilities for the financial statements statements and the audit Our Opinion Our responsibilities and those of the directors In our opinion, the parent company financial statements dened As explained more fully in the Directors statement of below: responsibilities set out on page 211, the directors are responsible for the preparation of the financial statements and for being give a true and fair view of the state of the parent companys satisfied that they give a true and fair view.
affairs as at 31 December 2014: have been properly prepared in accordance with United Our responsibility is to audit and express an opinion on the Kingdom Generally Accepted Accounting Practice: and financial statements in accordance with applicable law and ISAs have been prepared in accordance with the requirements UK & Ireland.
Those standards require us to comply with the of the Companies Act 2006.
Auditing Practices Boards Ethical Standards for Auditors.
What we have audited This report, including the opinions, has been prepared for and only GlaxoSmithKline plcs financial statements comprise: for the companys members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose.
the Company balance sheet as at 31 December 2014: and We do not, in giving these opinions, accept or assume the notes to the Company balance sheet, which include a responsibility for any other purpose or to any other person to whom summary of significant accounting policies and other explanatory this report is shown or into whose hands it may come save where information.
expressly agreed by our prior consent in writing.
The financial reporting framework that has been applied in the preparation of the financial statements is applicable law and What an audit of financial statements involves United Kingdom Accounting Standards United Kingdom We conducted our audit in accordance with ISAs UK & Ireland.
An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable Other required reporting assurance that the financial statements are free from material misstatement, whether caused by fraud or error.
This includes Consistency of other information an assessment of: Companies Act 2006 opinion In our opinion, the information given in the Strategic Report whether the accounting policies are appropriate to the parent and the Directors Report for the financial year for which the companys circumstances and have been consistently applied financial statements are prepared is consistent with the and adequately disclosed: financial statements.
the reasonableness of significant accounting estimates made ISAs UK & Ireland reporting by the directors: and Under International Standards on Auditing UK and Ireland the overall presentation of the financial statements.
ISAs UK & Ireland we are required to report to you if, in our opinion, information in the Annual Report is: We primarily focus our work in these areas by assessing the materially inconsistent with the information in the audited directors judgements against available evidence, forming our financial statements: or own judgements, and evaluating the disclosures in the financial statements.
apparently materially incorrect based on, or materially inconsistent with, our knowledge of the company acquired We test and examine information, using sampling and other in the course of performing our` audit: or auditing techniques, to the extent we consider necessary to otherwise misleading.
provide a reasonable basis for us to draw conclusions.
We obtain audit evidence through testing the effectiveness of controls, We have no exceptions to report arising from this responsibility.
substantive procedures or a combination of both.
Adequacy of accounting records and information and In addition, we read all the financial and non-financial information explanations received in the Annual Report to identify material inconsistencies with the Under the Companies Act 2006 we are required to report to you audited financial statements and to identify any information that is if, in our opinion: apparently materially incorrect based on, or materially inconsistent we have not received all the information and explanations we with, the knowledge acquired by us in the course of performing the require for our audit: or audit.
If we become aware of any apparent material misstatements adequate accounting records have not been kept by the parent or inconsistencies we consider the implications for our report.
company, or returns adequate for our audit have not been received from branches not visited by us: or Other matter the financial statements and the part of the Directors We have reported separately on the group financial statements Remuneration report to be audited are not in agreement with the of GlaxoSmithKline plc for the year ended 31 December 2014. accounting records and returns.
The company has passed a resolution in accordance with section We have no exceptions to report arising from this responsibility.
506 of the Companies Act 2006 that the senior statutory auditors Directors remuneration name should not be stated.
Directors Remuneration report Companies Act 2006 opinion In our opinion, the part of the Directors Remuneration Report to  LLP be audited has been properly prepared in accordance with the Chartered Accountants and Statutory Auditors Companies Act 2006.
London 26 February 2015 Other Companies Act 2006 reporting Under the Companies Act 2006 we are required to report to you if, in our opinion, certain disclosures of directors remuneration specified by law are not made.
We have no exceptions to report arising from this responsibility.
212 GSK Annual Report 2014 Strategic report Governance & remuneration Financial statements Investor information Company balance sheet UK GAAP at 31 December 2014 2014 2013 Notes m m Fixed assets investments E 19,691 19,691 Debtors F 10,900 3,358 Cash at bank 2 12 Current assets 10,902 3,370 Creditors: amounts due within one year G 1,799 531 Net current assets 9,103 2,839 Total assets less current liabilities 28,794 22,530 Provisions for liabilities H 25 Net assets 28,769 22,530 Capital and reserves Called up share capital I 1,339 1,336 Share premium account I 2,759 2,595 Other reserves J 1,420 1,420 profit and loss account J 23,251 17,179 Equity shareholders funds 28,769 22,530 The financial statements on pages 213 to 216 were approved by the Board on 26 February 2015 and signed on its behalf by Sir Christopher Gent Chairman GlaxoSmithKline plc Registered number: 3888792 GSK Annual Report 2014 213 Strategic report Governance & remuneration Financial statements Investor information Expenditure Notes to the company balance sheet Expenditure is recognised in respect of goods and services UK GAAP received when supplied in accordance with contractual terms.
A Presentation of the financial statements Provision is made when an obligation exists for a future liability Description of business in respect of a past event and where the amount of the obligation GlaxoSmithKline plc is the parent company of GSK, a major global can be reliably estimated.
healthcare group which is engaged in the creation and discovery, Investments in subsidiary companies development, manufacture and marketing of pharmaceutical Investments in subsidiary companies are held at cost less any products, including vaccines, over-the-counter OTC medicines provision for impairment.
Impairment of investments Preparation of financial statements The carrying value of investments are reviewed for impairment The financial statements, which are prepared on a going concern when there is an indication that the investment might be impaired.
basis, are drawn up in accordance with UK Generally Accepted Any provision resulting from an impairment review is charged to Accounting Practice UK GAAP and with UK accounting the income statement in the year concerned.
presentation as at 31 December 2014, with comparative gures as at 31 December 2013.
Where appropriate, comparative gures Share based payments are reclassied to ensure a consistent presentation with current The issuance by the company to its subsidiaries of a grant over year information.
the companys shares, represents additional capital contributions by the company in its subsidiaries.
An additional investment in As permitted by section 408 of the Companies Act 2006, subsidiaries results in a corresponding increase in shareholders the profit and loss account of the company is not presented equity.
The additional capital contribution is based on the fair value in this Annual Report.
of the grant issued, allocated over the underlying grants vesting The company is included in the Group financial statements of period.
GlaxoSmithKline plc, which are publicly available.
Advantage Taxation has been taken of the exemption provided by FRS 1 Cash ow Current tax is provided at the amounts expected to be paid statements revised 1996 not to prepare a cash ow applying tax rates that have been enacted or substantively statement and of the exemption provided by FRS 8 Related enacted by the balance sheet date.
party disclosures not to disclose any related party transactions The company accounts for taxation which is deferred or within the Group.
accelerated by reason of timing differences which have originated Accounting convention and standards but not reversed by the balance sheet date.
Deferred tax assets The balance sheet has been prepared using the historical are only recognised to the extent that they are considered cost convention and complies with applicable UK accounting recoverable against future taxable profits.
Deferred tax is measured at the average tax rates that are expected Accounting principles and policies to apply in the periods in which the timing differences are expected The preparation of the balance sheet in conformity with generally to reverse.
Deferred tax liabilities and assets are not discounted.
accepted accounting principles requires management to make Financial guarantees estimates and assumptions that affect the reported amounts of Liabilities relating to guarantees issued by the company on behalf assets and liabilities and disclosure of contingent assets and of its subsidiaries are initially recognised at fair value and liabilities at the date of the balance sheet.
Actual amounts could amortised over the life of the guarantee.
Legal and other disputes The balance sheet has been prepared in accordance with the The company provides for anticipated settlement costs where companys accounting policies approved by the Board and an outow of resources is considered probable and a reliable described in Note B. estimate may be made of the likely outcome of the dispute and B Accounting policies legal and other expenses arising from claims against the company.
Foreign currency transactions C Operating profit Foreign currency transactions are recorded at the exchange rate A fee of 11,523 2013 10,299 relating to the audit of the ruling on the date of transaction, or at the forward rate if hedged company has been charged in operating profit.
Foreign currency assets and liabilities are translated at rates of exchange ruling at the balance D Dividends sheet date, or at the forward rate.
The directors declared four interim dividends resulting in a dividend for the year of 80 pence, a 2 pence increase on the Dividends paid and received dividend for 2013.
For further details, see Note 16 to the Group Dividends paid and received are included in the financial financial statements, Dividends.
statements in the period in which the related dividends are actually paid or received.
214 GSK Annual Report 2014 Strategic report Governance & remuneration Financial statements Investor information Notes to the company balance sheet UK GAAP continued E Fixed assets investments 2014 2013 m m Shares in GlaxoSmithKline Services Unlimited 613 613 Shares in GlaxoSmithKline Holdings One Limited 18 18 Shares in GlaxoSmithKline Holdings Limited 17,888 17,888 Shares in GlaxoSmithKline Mercury Limited 33 33 18,552 18,552 Capital contribution relating to share based payments 1,139 1,139 19,691 19,691 F Debtors 2014 2013 m m Amounts due within one year: UK Corporation tax recoverable 205 203 Other receivables 3 Deferred tax recoverable 205 Amounts owed by Group undertakings 10,055 2,761 10,468 2,964 Amounts due after more than one year: Amounts owed by Group undertakings 432 394 10,900 3,358 The deferred tax asset arises as a result of the recognition of deferred tax on tax losses expected to be used on completion of the Novartis transaction.
G Creditors 2014 2013 m m Amounts due within one year: Bank overdraft 10 Other creditors 497 460 Amounts owed to Group undertakings 1,302 61 1,799 531 The company has guaranteed debt issued by one of its subsidiary companies for which it receives an annual fee from the subsidiary.
In aggregate, the company has outstanding guarantees over $9 billion of debt instruments.
The amounts due from the subsidiary companies in relation to these guarantee fees will be recovered over the life of the bonds and are disclosed within debtors see Note F. H Provisions for liabilities 2014 2013 m m At 1 January Charge for the year 148 Utilised 138 Other movements 15 At 31 December 25 The provisions for liabilities relate to a number of legal and other disputes in which the company is currently involved.
GSK Annual Report 2014 215 Strategic report Governance & remuneration Financial statements Investor information Notes to the company balance sheet UK GAAP continued I Called up share capital and share premium account Share premium Ordinary Shares of 25p each account Number m m Share capital authorised At 31 December 2013 10,000,000,000 2,500 At 31 December 2014 10,000,000,000 2,500 Share capital issued and fully paid At 1 January 2013 5,397,595,969 1,349 2,022 Issued under employee share schemes 44,610,727 12 573 Share capital cancelled 100,000,000 25 At 31 December 2013 5,342,206,696 1,336 2,595 Issued under employee share schemes 13,090,536 3 164 At 31 December 2014 5,355,297,232 1,339 2,759 31 December 31 December 2014 2013 000 000 Number of shares issuable under outstanding options 88,801 91,303 Number of unissued shares not under option 4,555,902 4,566,351 At 31 December 2014, of the issued share capital, 52,734,605 shares were held in the ESOP Trusts, 491,515,950 shares were held as Treasury shares and 4,811,046,677 shares were in free issue.
All issued shares are fully paid.
The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 42, Employee share schemes.
A total of 15 million shares were purchased by the company during 2014 at a cost of 238 million.
J Reserves Other profit and reserves loss account Total m m m At 1 January 2013 1,393 22,401 23,794 profit attributable to shareholders 38 38 Dividends to shareholders 3,680 3,680 Shares purchased and cancelled or held as Treasury shares 25 1,504 1,479 Capital contribution relating to share based payments 2 2 At 31 December 2013 1,420 17,179 18,599 profit attributable to shareholders 10,003 10,003 Dividends to shareholders 3,843 3,843 Shares purchased and held as Treasury shares 238 238 Treasury shares transferred to the ESOT held by a subsidiary company 150 150 At 31 December 2014 1,420 23,251 24,671 The profit of GlaxoSmithKline plc for the year was 10,003 million 2013 38 million loss, which after dividends of 3,843 million 2013 3,680 million, gave a retained profit of 6,160 million 2013 3,718 million loss.
After the cost of shares purchased and held as Treasury shares of 238 million 2013 1,504 million and the effect of the 150 million Treasury shares transferred to a subsidiary company 2013 nil, the profit and loss account reserve at 31 December 2014 stood at 23,251 million 2013 17,179 million, of which 4,096 million is unrealised 2013 4,096 million.
K Adoption of Financial Reporting Standard FRS 101 Reduced Disclosure Framework Following the publication of FRS 100 Application of Financial Reporting Requirements, GlaxoSmithKline plc is required to change its accounting framework for its entity financial statements, which is currently UK GAAP, for its financial year commencing 1 January 2015.
It considers that it is in the best interests of the Group for GlaxoSmithKline plc to adopt FRS 101.
No disclosures in the current financial statements would be omitted on adoption of FRS 101.
216 GSK Annual Report 2014 Strategic report Governance & remuneration Financial statements Investor information Investor information In this section Quarterly trend 218 Five year record 222 Product development pipeline 225 Products, competition and intellectual property 229 Risk factors 232 Share capital and share price 242 Dividends 244 Tax information for shareholders 244 Annual General Meeting 2015 245 US law and regulation 247 Shareholder services and contacts 249 Glossary of terms and index 251 G GS SK A K An nn nu ua all R Re ep po or rt t 2 20 01 14 4 21 217 7
